JPRN-UMIN000006858已完成未知
Recearch for the role of the action of GLP-1 on normal glucose tolerance - Recearch for the role of the action of GLP-1 on normal glucose tolerance
Division of Diabetes and Enocrinology Kobe University Graduate School of Medicine0 个研究点目标入组 14 人开始时间: 2011年12月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
Exenatide, but not liraglutide, markedly decelerated the peak of both plasma glucose and serum insulin levels during the OGTT, with the peaks of both glucose and insulin concentrations occurring at 150min after test initiation with exenatide compared with 30min in the control condition or with liraglutide. Exenatide and liraglutide reduced the area under the curve for plasma glucose levels during the OGTT by similar extents, whereas that for serum insulin levels was reduced only by exenatide.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •ad lib blood glucose >= 200 mg/dl hypersensitivity for the drugs pregnancy or the possibility HbA1c >= 6.1% severe renal dysfunction and liver function Considering unsuitable for this research with other reasons
研究者
相似试验
终止
4 期
GLP-1 and Non-exercise Activity Thermogenesis in RHZType 2 Diabetes MellitusNCT01638260Maastricht University Medical Center22
进行中（未招募）
不适用
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension period followed by an additional 38-week, non-randomised extension period followed by an additional 38-week, non-randomised extension period.type 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-006092-21-ATovo Nordisk a/s723
进行中（未招募）
1 期
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension periodEUCTR2006-006092-21-FRovo Nordisk a/s
进行中（未招募）
不适用
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension period followed by an additional 38-week, non-randomised extension period.type 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-006092-21-DEovo Nordisk A/S723
进行中（未招募）
不适用
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension period followed by an additional 38-week, non-randomised extension periodtype 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-006092-21-SEovo Nordisk a/s723